<DOC>
	<DOCNO>NCT02206035</DOCNO>
	<brief_summary>This phase II open label trial design evaluate efficacy Tac/MTX/Toc prevent graft versus host disease ( GVHD ) . Outcomes patient clinical trial compare contemporary control CIBMTR .</brief_summary>
	<brief_title>Phase II Open Label Trial Of Tacrolimus/Methotrexate And Tocilizumab For The Prevention Of Acute Graft Versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description>This Phase II open label trial design evaluate efficacy Tacrolimus , Methotrexate Tocilizumab ( Tac/MTX/Toc ) prevent graft versus host disease ( GVHD ) allogeneic hematopoietic stem cell transplantation compare contemporary control cohort select Center International Bone Marrow Transplant Research ( CIBMTR ) treat standard methotrexate tacrolimus GVHD prevention . The control group patient satisfy similar eligibility requirement patient enrol clinical trial match relevant clinical variable ( age , sex , condition regimen , disease , graft source , etc ) . Patients enrol clinical trial receive tacrolimus per institutional guideline dos maintain therapeutic level continue least Day 90 post transplant . Methotrexate dose 15 mg/m2 Day +1 10mg/m2 Days +3 , +6 +11 . Tocilizumab administer intravenously dose 8 mg/kg Day -1 . Ancillary Study : The ancillary study evaluate whether tocilizumab effective positively impact mood , fatigue , sleep , pain group individual undergo allogeneic hematopoietic stem cell transplantation compare individual receive tocilizumab . We also assess whether tocilizumab alters gene expression Rap1 prenylation manner may reduce progression relapse cancer transplant .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>1 . Age &gt; =18 year 2 . Patients acute leukemia , chronic myelogenous leukemia , myeloproliferative disease myelodysplasia le 5 % blast bone marrow 3 . Patients chronic lymphocytic leukemia/small lymphocytic lymphoma , NonHodgkin Lymphoma Hodgkin Disease chemosensitive disease time transplant 4 . Planned conditioning regimen include combination busulfan fludarabine busulfan cyclophosphamide 5 . Transplantation Tcellreplete graft 6 . Bone marrow mobilize peripheral blood cell graft 7 . Patients must either sibling donor ( 6/6 match HLAA , B DRB1 ) unrelated donor ( 8/8 match HLAA , B , C DRB1 ) 8 . Cardiac function : Ejection fraction rest &gt; 45 % myeloablative conditioning &gt; 40 % reduce intensity condition 9 . Estimated creatinine clearance great 50 mL/minute ( use CockcroftGault formula actual body weight ) 10 . Pulmonary function : DLCO ≥40 % ( adjust hemoglobin ) FEV1≥50 % 11 . Liver function : total bilirubin &lt; 1.5 x upper limit normal ALT/AST &lt; 2.5x upper normal limit 12 . Signed informed consent 1 . Prior allogeneic HCT 2 . Karnofsky Performance Score &lt; 70 % 3 . Patients uncontrolled bacterial , viral fungal infection ( currently take medication progression infectious disease clinical improvement ) time enrollment 4 . Prior intolerance allergy Tocilizumab 5 . Use rituximab , alemtuzumab , ATG monoclonal antibody time condition regimen 6 . History diverticulitis , Crohn 's disease ulcerative colitis 7 . History demyelinate disorder 8 . Pregnant lactate woman 9 . Patients history rheumatologic disorder previously receive Tocilizumab Eligibility Control Arm Patients control arm identify patient report CIBMTR U.S center . Control patient require satisfy similar eligibility requirement patient enrol clinical trial . Patients need fulfill inclusion criterion clinical trial accord Section 2.4.1 , plus follow : 1 . Receive Tac/MTX sole GVHD prophylaxis approach 2 . Receive regimen specify Table 2.5 3 . Year transplant 2010 2013 Exclusion criterion control : 1 . Karnofsky Performance Score &lt; 70 % Data eligible patient use constitute control database study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>